<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05039567</url>
  </required_header>
  <id_info>
    <org_study_id>2019-1303-2</org_study_id>
    <nct_id>NCT05039567</nct_id>
  </id_info>
  <brief_title>Effect of an Optimal Heart Team Protocol on Decision-making Stability</brief_title>
  <official_title>The Effect of an Optimal Heart Team Implementation Protocol on the Stability of Decision-making for Complex Coronary Artery Disease-a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>China National Center for Cardiovascular Diseases</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>China National Center for Cardiovascular Diseases</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is aimed to evaluate the effect of the optimal heart team implementation protocol&#xD;
      on the stability of decision-making for patients with complex coronary artery disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Current guidelines recommend a heart team in the decision making for patients with complex&#xD;
      coronary artery disease (CAD). Previous study reported that the agreement between heart teams&#xD;
      for revascularization decision-making in complex CAD patients was moderate. Potential factors&#xD;
      associated with decision discrepancies were summarized in several aspects and a detailed&#xD;
      heart team implementation protocol was generated and further validation is needed. This study&#xD;
      is designed to evaluate the effect of the optimal heart team implementation protocol on the&#xD;
      stability of decision-making for patients with complex coronary artery disease.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">November 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall percent agreement</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>The proportion of patients who received unanimous decision recommendations from the heart team</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Kappa value of heart team decision-making</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>Fliess's (more than 2 raters) and Cohen's (2 raters) kappa coefficients to evaluate inter-team, inter-specialist, and inter-round agreement for treatment decisions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inappropriate decision rate</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>According to the American College of Cardiology/American Association for Thoracic Surgery/American Heart Association 2017 Appropriate Use Criteria for coronary revascularization, the inappropriate decision rate od decision-making</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compliance rate in real-world treatment</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>Compliance is defined as the patient's actual treatment meeting the recommendations of either heart team</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reproducibility of decision-making</measure>
    <time_frame>At 1-month after first phase of heart team meeting</time_frame>
    <description>All cases will be discussed by the same heart team to evaluate the intra-team consistency in decision-making.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">84</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>optimal heart team group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Heart teams in this group will be established according to the optimal heart team protocol. Each team consists of two interventional cardiologists and two cardiac surgeons. Team members will be trained systematically before the heart team meeting.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>conventional heart team group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Heart teams in this group will be established according to the basic elements recommended by guidelines. Each team consists of an interventional cardiologist, a cardiac surgeon, and a non-interventional cardiologist. No team training will be held before the heart team meeting.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>optimal heart team protocol</intervention_name>
    <description>Heart teams in the experimental group will be established and trained based on the optimal heart team implementation protocol. The protocol included instructions on specialist selection, specialist training, team composition, team training and formal implementation precess.</description>
    <arm_group_label>optimal heart team group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Eligibility Criteria for patients:&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
        Patients with stable CAD according to the National Cardiovascular Data Registry (NCDR)&#xD;
        CathPCI criteria (stable angina, no or silent myocardial ischemia) and angiographically&#xD;
        confirmed 3-vessel disease or left main disease.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. prior percutaneous coronary intervention (PCI) or coronary artery bypass grafting&#xD;
             (CABG);&#xD;
&#xD;
          2. cardiac troponin I (CTnI) greater than the local laboratory upper limit of normal or&#xD;
             recent myocardial infarction with CTnI levels still elevated;&#xD;
&#xD;
          3. concomitant severe valvular disease, macrovascular disease, or huge ventricular&#xD;
             aneurysm requiring surgery;&#xD;
&#xD;
          4. concomitant atrial fibrillation or severe arrhythmia&#xD;
&#xD;
        Eligibility Criteria for specialists:&#xD;
&#xD;
        Inclusion Criteria for interventional cardiologists:&#xD;
&#xD;
          1. Annual PCI volume ≥200&#xD;
&#xD;
          2. Annual left main PCI volume ≥25&#xD;
&#xD;
          3. Capable of chronic total occlusion(CTO) PCI&#xD;
&#xD;
          4. Clinical researcher experience in coronary revascularization&#xD;
&#xD;
          5. Proficient in clinical guidelines&#xD;
&#xD;
        Inclusion Criteria for cardiac surgeons:&#xD;
&#xD;
          1. CABG total volume ≥200&#xD;
&#xD;
          2. Proficient in both on-pump and off-pump CABG&#xD;
&#xD;
          3. Clinical researcher experience in coronary revascularization&#xD;
&#xD;
          4. Proficient in clinical guidelines&#xD;
&#xD;
        Inclusion Criteria for non-interventional cardiologists:&#xD;
&#xD;
        1) Proficient in clinical guidelines&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhe Zheng, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fuwai Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhe Zheng, MD,PhD</last_name>
    <phone>+86-010-88396051</phone>
    <email>zhengzhe@fuwai.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hanping Ma, MD</last_name>
    <phone>+86-15010906199</phone>
    <email>mahp_michelle@163.com</email>
  </overall_contact_backup>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 26, 2021</study_first_submitted>
  <study_first_submitted_qc>September 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 9, 2021</study_first_posted>
  <last_update_submitted>September 8, 2021</last_update_submitted>
  <last_update_submitted_qc>September 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Heart Team protocol</keyword>
  <keyword>Coronary Artery Disease</keyword>
  <keyword>decision-making agreement</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

